ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

GlaxoSmithKline and Hansoh Pharmaceutical Group side by side

Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.

At a glance

Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.

GlaxoSmithKlineHansoh Pharmaceutical Group
studies on the registry4,198190
open to participants now136117
phase 3 studies under way7821
reach primary completion within a year6727
programswith a study of their own in two years88+17 named only42

Pipeline by phase

Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.

Furthest phaseGlaxoSmithKlineHansoh Pharmaceutical Group
Phase 1

GlaxoSmithKline: 19 of its 88 programs at phase 1

  1. Pn-MAPS30plusphase 1
  2. GSK4771261phase 1
  3. Antibody-drug Conjugate GSK5533524phase 1
  4. ganfeborolephase 1
  5. GSK4425689Aphase 1

and 14 more — sign in to see them all

22%

Hansoh Pharmaceutical Group: 19 of its 42 programs at phase 1

  1. HS-20122phase 1
  2. HS-20136-2phase 1
  3. PARP1 Inhibitor HS-10502phase 1
  4. Alveltamigphase 1
  5. apatinibphase 1

and 14 more — sign in to see them all

45%
Phase 2

GlaxoSmithKline: 36 of its 88 programs at phase 2

  1. dezecapavirphase 2
  2. nelistotugphase 2
  3. GSK3862995Bphase 2
  4. VH4524184phase 2
  5. nirogacestatphase 2

and 31 more — sign in to see them all

41%

Hansoh Pharmaceutical Group: 9 of its 42 programs at phase 2

  1. HS-20118phase 2
  2. HIF-2alpha Inhibitor HS-10516phase 2
  3. HS-10390phase 2
  4. HS-10542phase 2
  5. RET Inhibitor HS-10365phase 2

and 4 more — sign in to see them all

21%
Phase 3

GlaxoSmithKline: 23 of its 88 programs at phase 3

  1. belantamab mafodotinphase 3
  2. felcorekibartphase 3
  3. risvutatug rezetecanphase 3
  4. velzatinibphase 3
  5. efimosfermin alfaphase 3

and 18 more — sign in to see them all

26%

Hansoh Pharmaceutical Group: 13 of its 42 programs at phase 3

  1. risvutatug rezetecanphase 3
  2. HS-10504phase 3
  3. HS-10506phase 3
  4. aumolertinibphase 3
  5. mocertatug rezetecanphase 3

and 8 more — sign in to see them all

31%
Approved, new studies

GlaxoSmithKline: 10 of its 88 programs at approved, new studies

  1. dostarlimabapproved, new study
  2. cabotegravirapproved, new study
  3. depemokimabapproved, new study
  4. belimumabapproved, new study
  5. niraparibapproved, new study

and 5 more — sign in to see them all

11%

Hansoh Pharmaceutical Group: 1 of its 42 programs at approved, new studies

  1. tenofovir amibufenamideapproved, new study
2%

Readouts ahead

Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.

Nov ’26DecJan ’27FebMarAprMayJunJulAugSepOct
GlaxoSmithKline40 readouts · 8 phase 3

GlaxoSmithKline, Nov ’26: 4 programs whose next study reaches primary completion, 2 in phase 3

  1. Pn-MAPS30plusphase 1 · Nov 19 · NCT07428759
  2. dostarlimabapproved, new study · Nov 23 · NCT06567782
  3. Pentetic Acidphase 3 · Nov 23 · NCT07596199
  4. niraparibapproved, new study · Nov 26 · NCT03981796

GlaxoSmithKline, Dec ’26: 6 programs whose next study reaches primary completion, 2 in phase 3

  1. Investigational mRNA Seasonal Flu/COVID-19 Combination (Flu/COVm) Vaccinephase 1 · Dec 3 · NCT07464314
  2. momelotinibphase 3 · Dec 11 · NCT03441113
  3. GSK3862995Bphase 2 · Dec 16 · NCT06154837
  4. HFA-152aphase 3 · Dec 28 · NCT07645248
  5. norfluranephase 3 · Dec 28 · NCT07645248

and 1 more — sign in to see them all

GlaxoSmithKline, Jan ’27: 4 programs whose next study reaches primary completion

  1. Adjuvanted RSVPreF3 vaccinephase 2 · Jan 12 · NCT07092865
  2. velzatinibphase 3 · Jan 12 · NCT07862114
  3. SOC INSTI-based ARTphase 1 · Jan 22 · NCT07053384
  4. VH3810109phase 2 · Jan 22 · NCT07053384

GlaxoSmithKline, Feb ’27: 1 program whose next study reaches primary completion

  1. dezecapavirphase 2 · Feb 18 · NCT07934719

GlaxoSmithKline, Mar ’27: 6 programs whose next study reaches primary completion, 1 in phase 3

  1. depemokimabapproved, new study · Mar 1 · NCT07671001
  2. CAB ULAphase 3 · Mar 8 · NCT06786520
  3. cabotegravirapproved, new study · Mar 8 · NCT06786520
  4. camlipixantphase 3 · Mar 9 · NCT07519395
  5. ozureprubartphase 2 · Mar 16 · NCT07220811

and 1 more — sign in to see them all

GlaxoSmithKline, Apr ’27: 2 programs whose next study reaches primary completion

  1. felcorekibartphase 3 · Apr 13 · NCT07712393
  2. as01ephase 2 · Apr 23 · NCT07036159

GlaxoSmithKline, May ’27: 5 programs whose next study reaches primary completion

  1. Candidate UTI vaccine HTD formulation 2phase 2 · May 3 · NCT06702449
  2. Candidate UTI vaccine low dose formulation 1phase 2 · May 3 · NCT06702449
  3. VH4770359phase 1 · May 5 · NCT07525544
  4. gepotidacinphase 3 · May 17 · NCT07645235
  5. GSK4771261phase 1 · May 20 · NCT07600450

GlaxoSmithKline, Jun ’27: 4 programs whose next study reaches primary completion, 1 in phase 3

  1. Bevacizumabphase 2 · Jun 21 · NCT06796907
  2. belimumabapproved, new study · Jun 29 · NCT06411249
  3. Low dose Strep A Alumphase 1 · Jun 29 · NCT07085702
  4. Low dose Strep A AS37phase 1 · Jun 29 · NCT07085702

GlaxoSmithKline, Jul ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. mRNA Seasonal Flu vaccinephase 3 · Jul 9 · NCT07851246

GlaxoSmithKline, Aug ’27: 2 programs whose next study reaches primary completion, 1 in phase 3

  1. belantamabphase 2 · Aug 5 · NCT07742527
  2. shingrixapproved, new study · Aug 23 · NCT05371080

GlaxoSmithKline, Sep ’27: 1 program whose next study reaches primary completion

  1. mocertatug rezetecanphase 3 · Sep 22 · NCT06431594

GlaxoSmithKline, Oct ’27: 4 programs whose next study reaches primary completion

  1. GSK3772701phase 2 · Oct 8 · NCT07545681
  2. efimosfermin alfaphase 3 · Oct 13 · NCT07358546
  3. Anti-PSMA/Anti-CD3 T-cell Engager GSK5458514phase 2 · Oct 26 · NCT06990880
  4. VH4524184phase 2 · Oct 28 · NCT07202546
Hansoh Pharmaceutical Group15 readouts · 2 phase 3

Hansoh Pharmaceutical Group, Nov ’26: 1 program whose next study reaches primary completion

  1. HS-10504phase 3 · Nov 19 · NCT07685041

Hansoh Pharmaceutical Group, Dec ’26: 4 programs whose next study reaches primary completion

  1. HS-20118phase 2 · Dec 25 · NCT07896915
  2. risvutatug rezetecanphase 3 · Dec 30 · NCT06699576
  3. Anti-CDH17 Antibody-drug Conjugate HS-20110phase 2 · Dec 31 · NCT06892379
  4. HS-20136-2phase 1 · Dec 31 · NCT07483437

Hansoh Pharmaceutical Group, Jan ’27: 2 programs whose next study reaches primary completion

  1. HS-20152phase 1 · Jan 1 · NCT07503015
  2. HS-10522phase 1 · Jan 20 · NCT07609875

Hansoh Pharmaceutical Group, Feb ’27: 1 program whose next study reaches primary completion

  1. Embibatinibphase 3 · Feb 0 · NCT07933224

Hansoh Pharmaceutical Group, Mar ’27: 3 programs whose next study reaches primary completion, 2 in phase 3

  1. HS-20137phase 3 · Mar 1 · NCT07879885
  2. mocertatug rezetecanphase 3 · Mar 7 · NCT06855069
  3. olatorepatidephase 3 · Mar 30 · NCT07156500
·

Hansoh Pharmaceutical Group, May ’27: 2 programs whose next study reaches primary completion

  1. HS-10542phase 2 · May 30 · NCT07470762
  2. HS-10582phase 1 · May 30 · NCT07777003
·

Hansoh Pharmaceutical Group, Jul ’27: 1 program whose next study reaches primary completion

  1. HIF-2alpha Inhibitor HS-10516phase 2 · Jul 10 · NCT07097935

Hansoh Pharmaceutical Group, Aug ’27: 1 program whose next study reaches primary completion

  1. RET Inhibitor HS-10365phase 2 · Aug 31 · NCT06147570
··
size: programs that monthincludes phase 3Dates are estimates the sponsors file and often move.

Changed in the last 90 days

Since Aug 22, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.

GlaxoSmithKline

New programs 4

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 10

Hansoh Pharmaceutical Group

New programs 1

  • HS-20197phase 1 · first study · Sep 10

Reached a new phase 2

Study stopped 0

None

Primary completion later 0

None

Where they overlap

Conditions where at least two of them have programs: 13 in all, the first 12 here. A program counts in each condition its studies name most.

ConditionGlaxoSmithKlineHansoh Pharmaceutical Group
Carcinoma, Non-Small-Cell Lungboth · compare here

GlaxoSmithKline in Carcinoma, Non-Small-Cell Lung: 8 programs

  1. risvutatug rezetecanphase 3
  2. momelotinibphase 3
  3. neladalkibphase 3
  4. feladilimabphase 3
  5. nelistotugphase 2

and 3 more — sign in to see them all

Their studies: GlaxoSmithKline’s studies of Carcinoma, Non-Small-Cell Lung in search

Hansoh Pharmaceutical Group in Carcinoma, Non-Small-Cell Lung: 10 programs

  1. risvutatug rezetecanphase 3
  2. HS-10504phase 3
  3. aumolertinibphase 3
  4. HS-20117phase 3
  5. dalmelitinibphase 3

and 5 more — sign in to see them all

Their studies: Hansoh Pharmaceutical Group’s studies of Carcinoma, Non-Small-Cell Lung in search

Neoplasmsboth · compare here

Hansoh Pharmaceutical Group in Neoplasms: 5 programs

  1. risvutatug rezetecanphase 3
  2. mocertatug rezetecanphase 3
  3. dalmelitinibphase 3
  4. adebrelimabphase 2
  5. apatinibphase 1

Their studies: Hansoh Pharmaceutical Group’s studies of Neoplasms in search

Ovarian Neoplasmsboth · compare here

GlaxoSmithKline in Ovarian Neoplasms: 6 programs

  1. mocertatug rezetecanphase 3
  2. nirogacestatphase 2
  3. Bevacizumabphase 2
  4. ivonescimabphase 2
  5. dostarlimabapproved, new study

and 1 more — sign in to see them all

Their studies: GlaxoSmithKline’s studies of Ovarian Neoplasms in search

Hansoh Pharmaceutical Group in Ovarian Neoplasms: 4 programs

  1. mocertatug rezetecanphase 3
  2. PARP1 Inhibitor HS-10502phase 1
  3. apatinibphase 1
  4. Platinum Compoundsphase 1

Their studies: Hansoh Pharmaceutical Group’s studies of Ovarian Neoplasms in search

Prostatic Neoplasmsboth · compare here

Hansoh Pharmaceutical Group in Prostatic Neoplasms: 3 programs

  1. risvutatug rezetecanphase 3
  2. Alveltamigphase 1
  3. HRS-5041phase 1

Their studies: Hansoh Pharmaceutical Group’s studies of Prostatic Neoplasms in search

Small Cell Lung Carcinomaboth · compare here

GlaxoSmithKline in Small Cell Lung Carcinoma: 2 programs

  1. risvutatug rezetecanphase 3
  2. ivonescimabphase 2

Their studies: GlaxoSmithKline’s studies of Small Cell Lung Carcinoma in search

Hansoh Pharmaceutical Group in Small Cell Lung Carcinoma: 4 programs

  1. risvutatug rezetecanphase 3
  2. adebrelimabphase 2
  3. Alveltamigphase 1
  4. Platinum Compoundsphase 1

Their studies: Hansoh Pharmaceutical Group’s studies of Small Cell Lung Carcinoma in search

Breast Neoplasmsboth · compare here

GlaxoSmithKline in Breast Neoplasms: 3 programs

  1. nirogacestatphase 2
  2. Bevacizumabphase 2
  3. niraparibapproved, new study

Their studies: GlaxoSmithKline’s studies of Breast Neoplasms in search

Hansoh Pharmaceutical Group in Breast Neoplasms: 1 program

  1. adebrelimabphase 2

Their studies: Hansoh Pharmaceutical Group’s studies of Breast Neoplasms in search

Hepatitis B, Chronicboth · compare here

GlaxoSmithKline in Hepatitis B, Chronic: 3 programs

  1. GSK-3965193phase 2
  2. bepirovirsenapproved, new study
  3. Lamivudineapproved, new study

Their studies: GlaxoSmithKline’s studies of Hepatitis B, Chronic in search

Hansoh Pharmaceutical Group in Hepatitis B, Chronic: 1 program

  1. tenofovir amibufenamideapproved, new study

Their studies: Hansoh Pharmaceutical Group’s studies of Hepatitis B, Chronic in search

Endometrial Neoplasmsboth · compare here

GlaxoSmithKline in Endometrial Neoplasms: 2 programs

  1. mocertatug rezetecanphase 3
  2. dostarlimabapproved, new study

Their studies: GlaxoSmithKline’s studies of Endometrial Neoplasms in search

Hansoh Pharmaceutical Group in Endometrial Neoplasms: 1 program

  1. mocertatug rezetecanphase 3

Their studies: Hansoh Pharmaceutical Group’s studies of Endometrial Neoplasms in search

Obesityboth · compare here

GlaxoSmithKline in Obesity: 1 program

  1. efimosfermin alfaphase 3

Their studies: GlaxoSmithKline’s studies of Obesity in search

Hansoh Pharmaceutical Group in Obesity: 2 programs

  1. olatorepatidephase 3
  2. HS-20136-2phase 1

Their studies: Hansoh Pharmaceutical Group’s studies of Obesity in search

Carcinoma, Hepatocellularboth · compare here

GlaxoSmithKline in Carcinoma, Hepatocellular: 1 program

  1. Bevacizumabphase 2

Their studies: GlaxoSmithKline’s studies of Carcinoma, Hepatocellular in search

Hansoh Pharmaceutical Group in Carcinoma, Hepatocellular: 1 program

  1. apatinibphase 1

Their studies: Hansoh Pharmaceutical Group’s studies of Carcinoma, Hepatocellular in search

Diabetes Mellitus, Type 2both · compare here

GlaxoSmithKline in Diabetes Mellitus, Type 2: 1 program

  1. linerixibatphase 3

Their studies: GlaxoSmithKline’s studies of Diabetes Mellitus, Type 2 in search

Hansoh Pharmaceutical Group in Diabetes Mellitus, Type 2: 1 program

  1. olatorepatidephase 3

Their studies: Hansoh Pharmaceutical Group’s studies of Diabetes Mellitus, Type 2 in search

Head and Neck Neoplasmsboth · compare here

GlaxoSmithKline in Head and Neck Neoplasms: 1 program

  1. feladilimabphase 3

Their studies: GlaxoSmithKline’s studies of Head and Neck Neoplasms in search

Hansoh Pharmaceutical Group in Head and Neck Neoplasms: 1 program

  1. Platinum Compoundsphase 1

Their studies: Hansoh Pharmaceutical Group’s studies of Head and Neck Neoplasms in search

Show all 13

Same targetBetaPro · free during the beta

Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.

A target, or a pathogen for a vaccine, known for: GlaxoSmithKline 65 of 88 · Hansoh Pharmaceutical Group 29 of 42 programs (25 of them by rule). Most early programs are named only by a code and their companies do not say what they act on, so this list is short and grows as targets are read.

What this can't show

  • Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
  • Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
  • Readout dates are the sponsors’ estimates, not results.
  • A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
  • “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.
  • Programs a company names but has not registered are counted apart (GlaxoSmithKline: 17).